About Claris Bio
Claris Bio is a company based in Jersey City (United States) founded in 2018 by Sunil Chauhan, Clarke Atwell, and Reza Dana. It operates as a HealthTech. Claris Bio has raised $280.5 million across 5 funding rounds from investors including RA Capital, Novo Holdings and Mass General Brigham Ventures. Claris Bio offers products and services including CSB-001. Claris Bio operates in a competitive market with competitors including Ilya Pharma, QBiotics, MediWound, Aurion Biotech and Resolution Therapeutics, among others.
- Headquarter Jersey City, United States
- Founders Sunil Chauhan, Clarke Atwell, Reza Dana
- SectorsHealthcare
- Website clarisbio.com
- Legal Name Claris Biotherapeutics
- Total Equity Funding$280.5M (USD)
in 5 rounds
- Latest Funding Round$118M (USD), Series B
Jul 2026
- InvestorsRA Capital
& 10 more
Products & Services of Claris Bio
Claris Bio offers a comprehensive portfolio of products and services, including CSB-001.
A topical solution for corneal integrity restoration developed.
Funding Insights of Claris Bio
Claris Bio has successfully raised a total of $280.5M across 5 strategic funding rounds. The most recent funding activity was a Series B round of $118 million completed in July 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $280.5M
- Total Rounds 5
- Last Round Series B — $118M
- First Round $44.5M
(Dec 2023)
- Investors Count 11
All 5 funding rounds of Claris Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2026 | $118M | Series B | – | Samsara BioCapital, Catalio Capital Management | |
| Jul 2026 | $118M | Series B | – | Samsara BioCapital, Catalio Capital Management | |
| Sep 2025 | $2.3M | Debt – Conventional | – | – | – |
| Feb 2025 | $3.3M | Debt – Conventional | – | – | – |
| Dec 2023 | $44.5M | Series A | – | – |
11 investors in total: 10 institutional and 1 angel.
Investors in Claris Bio
Claris Bio has secured backing from 11 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include RA Capital, Novo Holdings and Mass General Brigham Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity and venture capital fund focused on the healthcare sector | – | novoholdings.dk | Hellerup, Denmark | |
- | – | massgeneralbrighamventures.com | - | |
- | – | samsaracap.com | - | |
- | – | cataliocapital.com | - | |
- | – | aislingcapital.com | - | |
- | – | janushenderson.com | - | |
- | – | sofinnova.com | - | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
- | – | massgeneralbrigham.org | - | |
- | – | adagecapital.com | - |
Investor details for Claris Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Claris Bio
3 people are tracked at Claris Bio (3 in leadership).
| Name | Role | Group |
|---|---|---|
Sunil Chauhan | Co-Founder | Leadership |
Clarke Atwell | Co-Founder & CEO | Leadership |
Reza Dana | Co-Founder | Leadership |
Complete people profiles for Claris Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Claris Bio
3 dated milestones of Claris Bio across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Claris Bio is founded.
- Funding First funding round of $44.5M.
- Funding Latest funding round, Series B, of $118.0M.
Competitors of Claris Bio
Claris Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Ilya Pharma, QBiotics, MediWound, Aurion Biotech and Resolution Therapeutics, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ilyapharma.se | 2016 | Uppsala, Sweden | $4.02M | – | Biological drugs for skin and mucosa wound treatment are developed. | |
| qbiotics.com | 2000 | Brisbane, Australia | $98.07M | – | Small molecules from plant extracts are developed for medical applications. | |
| mediwound.com | 2001 | Yavne, Israel | $18M | – | Enzymatic therapies for tissue repair and regeneration are developed. | |
| aurionbiotech.com | 2021 | Seattle, United States | $120M | – | Aurion Biotech is focused on developing advanced therapies for ocular diseases. | |
| resolution-tx.com | 2017 | Edinburgh, United Kingdom | $119.88M | 6 | Macrophage cell therapies are developed for inflammatory and liver diseases. | |
| sanuwave.com | 2005 | Alpharetta, United States | $1.43M | 38 | Noninvasive devices and biologics for wound healing are developed. | |
| tempothera.com | 2014 | San Diego, United States | $20.17M | – | Regenerative biomaterials for wounds are developed using particle technology. | |
| aurealistherapeutics.com | 2015 | Basel, Switzerland | $22.04M | – | Provider of cell & gene therapy platforms for chronic wounds, cancer, and inflammatory diseases | |
| stemsontx.com | 2019 | San Diego, United States | $22.5M | – | Stem cell-based therapy for hair growth is developed using iPSCs. | |
| tissueregenix.com | 2006 | Swillington, United Kingdom | – | 7 | Developer of regenerative medical devices by using cell technology |
Detailed competitors of Claris Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Claris Bio
Complete news archive for Claris Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Claris Bio
10 companies that operate in the same segment as Claris Bio (Ophthalmology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | – | 100 | |
Ophthalmic pharmaceuticals for diabetic macular edema are developed and commercialized. | 2003 | Alpharetta, Georgia, United States | USD 66.8 M | USD 80.75 M | 79 | |
AI-powered portable solutions for ophthalmic screening and diagnosis are developed. | 2009 | Bengaluru, Karnataka, India | USD 25.01 M | USD 4.85 M | 135 | |
Gene therapies for ocular and neurodegenerative diseases are developed. | 2015 | New York, New York, United States | – | USD 81.39 M | 381 | |
Small molecule therapeutics for ophthalmic disorders are developed. | 1987 | Watertown, United States | – | USD 31.37 M | 165 | |
Therapies for metabolic and orphan diseases are developed by Rezolute. | 2012 | Denver, Colorado, United States | – | – | 59 | |
Manufacturer of portable digital eye imaging devices and cloud-based healthcare platforms | 2010 | Bengaluru, Karnataka, India | USD 18.12 M | USD 4.78 M | 145 | |
Therapeutics for retinal diseases are developed by the company. | 2009 | Palo Alto, California, United States | USD 35.84 M | – | 109 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Claris Bio
Claris Bio was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Claris Bio is headquartered in Jersey City, United States. It is registered at Jersey City, New Jersey, United States.
Clarke Atwell is the current CEO of Claris Bio. They have also founded this company.
Claris Bio is a funded company, having raised a total of $280.5M across 5 funding rounds to date. The company's 1st funding round was a Series A of $44.5M, raised on Dec 2023.
Claris Bio is engaged in advancing corneal therapy through innovative biologic solutions. The company operates in the ophthalmology sector, targeting unmet medical needs with a focus on conditions like Limbal Stem Cell Deficiency (LCSD). Their lead program, CSB-001, is developed as a topical ocular biologic using hepatocyte growth factor (HGF) to restore structural and functional corneal integrity. Research and development efforts are supported by robust scientific data and partnerships with institutions like Massachusetts Eye and Ear Infirmary.
Claris Bio's top competitors include Ilya Pharma, Aurion Biotech and SanuWave.
Claris Bio offers CSB-001.
Claris Bio has 11 investors. Key investors include RA Capital, Novo Holdings, Mass General Brigham Ventures, Janus Henderson, and Samsara BioCapital.
Claris Bio operates through Claris Biotherapeutics.